Eterna Therapeutics (ERNA) had the highest return in 2016 by a US stock in the Biotechnology Industry, returning 4,959.5%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Eterna Therapeutics (ERNA) | 2016 | 4,959.52% |
Lunai Bioworks (LNAI) | 2016 | 3,650% |
Biocardia (BCDA) | 2016 | 1,442.86% |
Corbus Pharmaceuticals (CRBP) | 2016 | 409.04% |
TuHURA Biosciences (HURA) | 2016 | 242.9% |
PharmaCyte Biotech (PMCB) | 2016 | 200.81% |
Exelixis (EXEL) | 2016 | 171.09% |
ProMIS Neurosciences (PMN) | 2016 | 150% |
Biovie (BIVI) | 2016 | 143.8% |
Evotec SE ADR (EVO) | 2016 | 127.1% |
Anixa Biosciences (ANIX) | 2016 | 100.74% |
Minerva Neurosciences (NERV) | 2016 | 95.83% |
Xencor (XNCR) | 2016 | 86.93% |
Protagonist Therapeutics (PTGX) | 2016 | 83.25% |
Vanda Pharmaceuticals (VNDA) | 2016 | 75.47% |
MediciNova (MNOV) | 2016 | 67.5% |
AIxCrypto (AIXC) | 2016 | 66.26% |
Amarin (AMRN) | 2016 | 65.59% |
Matinas BioPharma (MTNB) | 2016 | 64.71% |
Assembly Biosciences (ASMB) | 2016 | 62% |
Fennec Pharmaceuticals (FENC) | 2016 | 47.48% |
Abeona Therapeutics (ABEO) | 2016 | 47.42% |
VivoSim Labs (VIVS) | 2016 | 38.93% |
InMed Pharmaceuticals (INM) | 2016 | 35.67% |
Crispr Therapeutics (CRSP) | 2016 | 35.07% |